<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRVM</journal-id><journal-title-group><journal-title>Asian Case Reports in Vascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2326-3490</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRVM.2017.51001</article-id><article-id pub-id-type="publisher-id">ACRVM-19858</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRVM20170100000_23986588.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  利奈唑胺补救治疗成人革兰阳性菌感染性心内膜炎的临床分析
  A Clinical Analysis of Linezolid as Rescue Treatment for Adult Gram-Positive Bacterial Infective Endocarditis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>文静</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陶</surname><given-names>臻</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>会玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>申</surname><given-names>玉英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南京医科大学附属南京医院 江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>tz1010@126.com(陶臻)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>02</month><year>2017</year></pub-date><volume>05</volume><issue>01</issue><fpage>1</fpage><lpage>6</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：通过临床病例回顾性研究，评价利奈唑胺补救治疗成人革兰阳性菌(G+)感染性心内膜炎(IE)的临床疗效及安全性。方法：收集南京医科大学附属南京医院感染科在2008年1月~2012年12月期间收治的确诊G+菌感染所致IE患者36例，其中利奈唑胺治疗组15例(以下简称为L组)，其他抗感染药物治疗组21例(以下简称对照组)；分析两组患者一般情况，比较两组患者治疗效果以及预后，数据处理通过SPSS软件。结果：两组患者均取得较好的疗效，L组与对照组的病死率分别为6.7%(1例)和9.5%(2例)，预后亦无显著性差异(P &gt; 0.05)；L组仅1例患者出现血小板下降的不良反应，停药后即好转，其他患者均耐受良好。结论：利奈唑胺用于G+菌IE的治疗可获得良好疗效，而且耐受性好。对多重耐药G+菌引起的IE，尤其对传统疗法有禁忌或治疗失败，是一个极具优势的治疗选择。 Objective: Retrospective study was carried out to evaluate the efficacy and safety of Linezolid as rescue treatment for adult gram-positive bacterial infective endocarditis. Methods: The study comprised 36 patients from department of infectious disease in Nanjing hospital affiliated to Nanjing Medical University, between 2008 and 2012. Fifteen patients enrolled in L group received Linezolid as rescue treatment for infective endocarditis which were unsuccessfully treated. Other twenty-one patients received conventional antibiotic therapy (Control group). We described baseline characteristics of the study population and compared L group with control group for the efficacy and the safety of treatment. The data were analyzed by SPSS software. Results: The thirty-three patients in two groups received effective treatment. No significant differences in the cure rate (80% vs. 81%) and in mortality (6.7% vs. 9.5%) were observed. Thrombocytopenia was present in only one patient of L group, and others were well tolerated. When we ended the Linezolid for treatment, the patients get well from thrombocytopenia. Conclusions: Linezolid was well tolerated and associated with the effective outcome as in patients with IE due to multiple resistant gram-positive, especially in patients who are fail to treated with conventional therapy or are poorly tolerated. 
   
  
  
 
</p></abstract><kwd-group><kwd>利奈唑胺，感染性心内膜炎, Linezolid</kwd><kwd> Infective Endocarditis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>利奈唑胺补救治疗成人革兰阳性菌感染性心内膜炎的临床分析<sup> </sup></title><p>王文静，陶臻<sup>*</sup>，吴会玲，申玉英</p><p>南京医科大学附属南京医院 江苏 南京</p><disp-formula id="hanspub.19858-formula1"><graphic xlink:href="http://html.hanspub.org/file/1-2470045x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年2月8日；录用日期：2017年2月25日；发布日期：2017年2月28日</p><disp-formula id="hanspub.19858-formula2"><graphic xlink:href="http://html.hanspub.org/file/1-2470045x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：通过临床病例回顾性研究，评价利奈唑胺补救治疗成人革兰阳性菌(G<sup>+</sup>)感染性心内膜炎(IE)的临床疗效及安全性。方法：收集南京医科大学附属南京医院感染科在2008年1月~2012年12月期间收治的确诊G<sup>+</sup>菌感染所致IE患者36例，其中利奈唑胺治疗组15例(以下简称为L组)，其他抗感染药物治疗组21例(以下简称对照组)；分析两组患者一般情况，比较两组患者治疗效果以及预后，数据处理通过SPSS软件。结果：两组患者均取得较好的疗效，L组与对照组的病死率分别为6.7%(1例)和9.5%(2例)，预后亦无显著性差异(P &gt; 0.05)；L组仅1例患者出现血小板下降的不良反应，停药后即好转，其他患者均耐受良好。结论：利奈唑胺用于G<sup>+</sup>菌IE的治疗可获得良好疗效，而且耐受性好。对多重耐药G<sup>+</sup>菌引起的IE，尤其对传统疗法有禁忌或治疗失败，是一个极具优势的治疗选择。</p><p>关键词 :利奈唑胺，感染性心内膜炎</p><disp-formula id="hanspub.19858-formula3"><graphic xlink:href="http://html.hanspub.org/file/1-2470045x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>感染性心内膜炎是一种重症感染性疾病，预后较差。尽管对该病诊断率已提高，及敏感抗生素的使用，感染性心内膜炎的病死率、致残率仍较高。随着多重耐药菌的增加，临床需要新的有效的抗生素。利奈唑胺是一种新型噁唑烷酮类抗生素，传统上主要用于治疗非心内膜炎的革兰阳性菌感染 [<xref ref-type="bibr" rid="hanspub.19858-ref1">1</xref>] 。Ⅲ期临床实验及动物实验均证实，利奈唑胺对包括凝固酶阴性的葡萄球菌、耐万古霉素的肠球菌及耐万古霉素的葡萄球菌在内的革兰阳性菌有确切疗效 [<xref ref-type="bibr" rid="hanspub.19858-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.19858-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.19858-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.19858-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.19858-ref6">6</xref>] 。虽然陆续有利奈唑胺用于治疗感染性心内膜炎的个案报道，但是在这一领域的数据仍较少 [<xref ref-type="bibr" rid="hanspub.19858-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.19858-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.19858-ref9">9</xref>] 。本文通过回顾性研究，评价利奈唑胺治疗成人革兰阳性菌感染性心内膜炎(IE)的临床疗效及安全性。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 纳入标准</title><p>1) 年龄在18~75岁之间。</p><p>2) 符合感染性心内膜炎诊断标准。</p><p>3) 2008年1月~2012年12月期间收治南京医科大学附属南京医院感染科的患者。</p><p>4) 血培养证实为G<sup>+</sup>菌感染。</p><p>5) 至少静脉使用利奈唑胺七天。</p></sec><sec id="s4_2"><title>2.2. 排除标准</title><p>1) 未能接受三个月随访。</p><p>2) 需要抗生素联合超出应用氨曲南治疗革兰阴性菌的范围的感染。</p></sec><sec id="s4_3"><title>2.3. 药敏试验</title><p>采用E试验检测对万古霉素等抗菌药的MIC，其中用K-B法测定病原菌对头孢哌酮舒巴坦的药敏。结果判读按2005年NCCLS (CLSI)标准。</p></sec><sec id="s4_4"><title>2.4. 疗效与安全性评价</title><p>首先，以院内死亡率为初始疗效评价。其次，以发生脑卒中、心源性休克，或使用利奈唑胺期间发生新的脓肿为第二疗效评价。治愈率按以下情况综合计算：自接受治疗起三月生存率、三月内感染性心内膜炎无复发、再燃及三月内未接受新的心脏手术。不良事件及实验室异常与使用药物关系分为肯定有关、可能有关、可无关或无关，以前三者计不良反应发生率。</p></sec><sec id="s4_5"><title>2.5. 统计学处理</title><p>通过SPSS17.0软件采用t检验及卡方检验对两组患者的基本情况、疗效等进行统计学分析。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 病例情况</title><p>共收集符合标准的36例病例，利奈唑胺治疗组15例(以下简称为L组)，其他抗感染药物治疗组21例(以下简称对照组)。两组患者间的年龄、性别、基础疾病及用药前体温等经分析差异无统计学意义，L组累及多瓣膜的患者6例(16.7%)，而对照组则仅有3例(8.3%)，两组间存在显著性差异(P &lt; 0.05)；L组患者伴有脏器功能损害及肺部感染的比例均高于对照组(P &lt; 0.05)，提示病情更为严重，见表1。两组患者在感染病原菌方面无显著性差异，见表2。</p></sec><sec id="s5_2"><title>3.2. 临床和实验室疗效</title><p>L组患者在使用利奈唑胺前均已接受了抗革兰阳性球菌抗生素的治疗。换用利奈唑胺的原因有初始药物疗效不佳(n = 9)、药物不耐受(n = 2)，出现肾损害(n = 3)及红人综合征(n = 1)。使用利奈唑胺抗感染平均为16.7天，均为静脉用药(600 mg每12小时一次)。8例患者单用利奈唑胺治疗，7例金黄色葡萄球菌感染患者利奈唑胺联合利福平治疗。</p><p>L组与对照组的院内病死率分别为6.7% (1例)和9.5% (2例)，无显著性差异(P &gt; 0.05)。在第二疗效评价及治愈率方面，也无统计学差异，具体见表3。</p></sec><sec id="s5_3"><title>3.3. 安全性评价</title><p>L组患者使用利奈唑胺作为补救治疗，原因见于L组中仅1例(8.3%)患者出现血小板下降的不良反应，停药后即好转。该患为62岁男性，静脉使用利奈唑胺两周后，血常规示血小板为30*10ˆ9/L，患者临床无明显出现倾向，停止使用利奈唑胺5天后血小板上升到103*10ˆ9/L。其他患者均耐受良好。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>利奈唑胺已经被广泛用于治疗由于革兰阳性菌感染引起的肺炎、脓毒症、皮肤及软组织感染。由于多重耐药菌的增加，利奈唑胺也开始被用来治疗如心内膜炎等其他器官、组织的感染。虽然感染性心内</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Subject characteristics at baselin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Baseline characteristics (基线)</th><th align="center" valign="middle" >Linezolid group (利奈唑胺组)</th><th align="center" valign="middle" >Controlled group (对照组)</th><th align="center" valign="middle" >P value (P值)</th></tr></thead><tr><td align="center" valign="middle" >No. of cases (病例数)</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender (female/male) 性别(女性/男性)</td><td align="center" valign="middle" >8/7</td><td align="center" valign="middle" >12/9</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >Age (χ &#177; s) 年龄</td><td align="center" valign="middle" >54 &#177; 13</td><td align="center" valign="middle" >56 &#177; 15</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >Main underlying diseases (no.) 主要基础疾病(病例数)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Diabetes mellitus (糖尿病)</td><td align="center" valign="middle" >6 (40%)</td><td align="center" valign="middle" >9 (42.9%)</td><td align="center" valign="middle" >0.569</td></tr><tr><td align="center" valign="middle" >Congenital heart disease (先天性心脏病)</td><td align="center" valign="middle" >4 (26.7%)</td><td align="center" valign="middle" >6 (28.6%)</td><td align="center" valign="middle" >0.602</td></tr><tr><td align="center" valign="middle" >Value redplace</td><td align="center" valign="middle" >9 (60%)</td><td align="center" valign="middle" >11 (52.4%)</td><td align="center" valign="middle" >0.456</td></tr><tr><td align="center" valign="middle" >Clinic manifestation 临床表现</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Fever (发热)</td><td align="center" valign="middle" >15 (100%)</td><td align="center" valign="middle" >21 (100%)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >Pneumonia (肺炎)</td><td align="center" valign="middle" >12 (33.3%)</td><td align="center" valign="middle" >7 (19.4%)</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >Kidney disfuction (肾功能不全)</td><td align="center" valign="middle" >6 (40%)</td><td align="center" valign="middle" >2 (8.3%)</td><td align="center" valign="middle" >0.039</td></tr><tr><td align="center" valign="middle" >Valves disease (瓣膜病变)</td><td align="center" valign="middle" >8 (16.7%)</td><td align="center" valign="middle" >3 (9.5%)</td><td align="center" valign="middle" >0.025</td></tr></tbody></table></table-wrap><p>表1. 两组患者基础情况比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Blood cultures result</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Microbial agent (No.) 病原菌</th><th align="center" valign="middle" >Linezolid group (利奈唑胺组)</th><th align="center" valign="middle" >Controlled group (对照组)</th></tr></thead><tr><td align="center" valign="middle" >Staphylococcus aureus 金黄色葡萄球菌</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >Streptococcus hominis 人链球菌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Hemolytic Streptococcus 溶血链球菌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Staphylococcus hominis 人葡萄球菌</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Staphylococcus epidermidis 表皮葡萄球菌</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Hemolytic Staphylococcus 溶血葡萄球菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Streptococcus mitis 轻型链球菌</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Streptococcus oralis 口腔链球菌</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Enterococcus faecalis 粪肠球菌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap><p>表2. 两组患者血培养结果</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Clinical efficacy of linezolid versus controlled group in subjects with I</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Linezolid group no. (利奈唑胺组)</th><th align="center" valign="middle" >Controlled group no. (对照组)</th><th align="center" valign="middle" >P value (P值)</th></tr></thead><tr><td align="center" valign="middle" >Stroke during treatment (治疗中出现中风)</td><td align="center" valign="middle" >1 (7%)</td><td align="center" valign="middle" >1 (5%)</td><td align="center" valign="middle" >0.667</td></tr><tr><td align="center" valign="middle" >New abscess (新的脓肿灶)</td><td align="center" valign="middle" >1 (7%)</td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" >0.417</td></tr><tr><td align="center" valign="middle" >Cardiogenic shock (心源性休克)</td><td align="center" valign="middle" >1 (7%)</td><td align="center" valign="middle" >1 (5%)</td><td align="center" valign="middle" >0.667</td></tr><tr><td align="center" valign="middle" >Relapse within 3 months after discharge (疗程结束后3个月内复发)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >P &gt; 0.05</td></tr><tr><td align="center" valign="middle" >Heart surgery within 3 months after discharge (疗程结束后3个月内外科手术治疗)</td><td align="center" valign="middle" >1 (7%)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.417</td></tr></tbody></table></table-wrap><p>表3. 两组疗效比</p><p>膜炎的标准治疗要求使用具有杀菌作用的抗菌药物，但是当多重耐药的G<sup>+</sup>菌引起的感染时，利奈唑胺的使用是必要的。利奈唑胺对绝大多数革兰阳性菌都有疗效，包括耐甲氧西林的金黄色葡萄球菌(MRSA)、万古霉素中敏的金黄色葡萄球菌(VISA)、耐青霉素的肺炎链球菌及耐万古霉素的肠球菌 [<xref ref-type="bibr" rid="hanspub.19858-ref1">1</xref>] 。</p><p>我们的研究发现，在治疗革兰阳性菌感染性心内膜炎上，利奈唑胺与其他抗菌药物相比，也能取得较好的疗效，而且患者的耐受性也较好。由于利奈唑胺是抑菌剂，所以在美国心脏病学会关于感染性心内膜炎治疗指南中并不被推荐用于一线治疗。Mancino等人 [<xref ref-type="bibr" rid="hanspub.19858-ref7">7</xref>] 曾汇总分析了从2000年1月份至2007年3月刊登的有关利奈唑胺治疗感染性心内膜炎的文献。他们总共检索到了46份病例。平均随访时间是8个半月，治愈率为71.7%，只有少数患者出现副作用。我们这项研究是回顾性的分析连续性病例，而且两组患者在疾病情况上无差异性。对照组根据美国和欧洲关于感染性心内膜炎治疗指南，给予传统的抗感染治疗方案。利奈唑胺组患者是接受了传统治疗方案后出现不能耐受的肾毒性或其他不良反应，而使用利奈唑胺作为补救治疗。</p><p>体外研究表明利奈唑胺是抑菌剂，所以利奈唑胺用于治疗感染性心内膜炎上存在争议，建议利奈唑胺最好与杀菌剂联合使用。在我们的研究中，利奈唑胺全是静脉给药，利奈唑胺的组织穿透力强，在心脏瓣膜及赘生物局部可达到高组织浓度。利奈唑胺的口服吸收较好，生物利用度100%，因此在将利奈唑胺由静脉改为口服的早期，不需要换药及调整药物剂量 [<xref ref-type="bibr" rid="hanspub.19858-ref10">10</xref>] 。</p><p>根据Vinh and Rubinstein [<xref ref-type="bibr" rid="hanspub.19858-ref3">3</xref>] 的研究，利奈唑胺长期使用(传统认为使用超过28天)可能会引起神经系统及血液系统方面的副作用。周围神经系统及视神经的毒副作用与使用时间长有关系，同时还会引起皮肤感觉异常、感觉运动失调及视物模糊 [<xref ref-type="bibr" rid="hanspub.19858-ref11">11</xref>] 。具体机制尚未明确，可能是通过与50s核糖小体上的23s的核糖核酸RNA结合，从而产生线粒体毒性，进而引起一系列副作用 [<xref ref-type="bibr" rid="hanspub.19858-ref12">12</xref>] 。这些症状是可逆的，一旦发生神经系统的副作用，需要立即停药。</p></sec><sec id="s7"><title>5. 结论</title><p>我们的研究表明，利奈唑胺在治疗G<sup>+</sup>菌感染性心内膜炎上，与传统治疗同样能取得较好的疗效。对多重耐药G<sup>+</sup>菌引起的IE，尤其对标准疗法有禁忌或治疗失败，或不能耐受糖肽类抗生素的患者来说，利奈唑胺是一个极具优势的治疗选择。当然我们的病例数较少、随访时间较短，还需进行较大规模的前瞻性随机对照性研究，来进一步评价利奈唑胺在治疗革兰阳性球菌心内膜炎的有效性和安全性。</p></sec><sec id="s8"><title>文章引用</title><p>王文静,陶 臻,吴会玲,申玉英. 利奈唑胺补救治疗成人革兰阳性菌感染性心内膜炎的临床分析 A Clinical Analysis of Linezolid as Rescue Treatment for Adult Gram-Positive Bacterial Infective Endocarditis[J]. 亚洲心脑血管病例研究, 2017, 05(01): 1-6. http://dx.doi.org/10.12677/ACRVM.2017.51001</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19858-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Moellering, R.C. (2003) Linezolid: The First Oxazolidinone Antimicrobial. Annals of Internal Medicine, 138, 135-142.  
&lt;br&gt;https://doi.org/10.7326/0003-4819-138-2-200301210-00015</mixed-citation></ref><ref id="hanspub.19858-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rubinstein, E., Isturiz, R., Standiford, H.C., et al. (2003) Worldwide Assessment of Linezolid’s Clinical Safety and Tolerability: Comparator Controlled Phase III Studies. Antimicrobial Agents and Chemotherapy, 47, 1824-1831.  
&lt;br&gt;https://doi.org/10.1128/AAC.47.6.1824-1831.2003</mixed-citation></ref><ref id="hanspub.19858-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Vinh, D.C. and Rubinstein, E. (2009) Linezolid: A Review of Safety and Tolerability. Journal of Infection, 59, S59- S74. &lt;br&gt;https://doi.org/10.1016/S0163-4453(09)60009-8</mixed-citation></ref><ref id="hanspub.19858-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Oramas-Shirey, M.P., Buchanan, L.V., Dileto-Fang, C.L., et al. (2001) Efficacy of Linezolid in a Staphylococcal Endocarditis Rabbit Model. Journal of Antimicrobial Chemotherapy, 47, 349-352. &lt;br&gt;https://doi.org/10.1093/jac/47.3.349</mixed-citation></ref><ref id="hanspub.19858-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Patel, R., Rouse, M.S., Piper, K.E. and Steckelberg, J.M. (2001) Linezolid Therapy of Vancomycin-Resistant Enterococcus Faeciumexperimental Endocarditis. Antimicrobial Agents and Chemotherapy, 45, 621-623.  
&lt;br&gt;https://doi.org/10.1128/AAC.45.2.621-623.2001</mixed-citation></ref><ref id="hanspub.19858-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tsaganos, T., Skiadas, I., Koutoukas, P. et al. (2008) Efficacy and Pharmacodynamics of Linezolid, Alone and in Combination with Rifampicin, in an Experimental Model of Methicillin-Resistant Staphylococcus Aureus Endocarditis. Journal of Antimicrobial Chemotherapy, 62, 381-383. &lt;br&gt;https://doi.org/10.1093/jac/dkn180</mixed-citation></ref><ref id="hanspub.19858-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mancino, P., Ucciferri, C., Falasca, K., Pizzigallo, E. and Vecchiet, J. (2008) Methicillin-Resistant Staphylococcus Epidermidis (MRSE) Endocarditis Treated with Linezolid. Scandinavian Journal of Infectious Diseases, 40, 67-73.  
&lt;br&gt;https://doi.org/10.1080/00365540701509915</mixed-citation></ref><ref id="hanspub.19858-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Muñoz, P., Rodríguez-Creixéms, M., Moreno, M., et al. (2007) Linezolid Therapy for Infective Endocarditis. Clinical Microbiology and Infection, 13, 211-215. &lt;br&gt;https://doi.org/10.1111/j.1469-0691.2006.01585.x</mixed-citation></ref><ref id="hanspub.19858-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lauridsen, T.K., Arpi, M. and Bruun, N.E. (2010) Linezolid Therapy for Infectious Endocarditis. Ugeskrift for Læger, 172, 1215-1216.</mixed-citation></ref><ref id="hanspub.19858-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Vardakas, K.Z., Kioumis, I. and Falagas, M.E. (2009) Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome. Current Drug Metabolism, 10, 2-12.  
&lt;br&gt;https://doi.org/10.2174/138920009787048446</mixed-citation></ref><ref id="hanspub.19858-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gould, F.K. (2011) Linezolid: Safety and Efficacy in Special Populations. Journal of Antimicrobial Chemotherapy, 66, iv3-iv6. &lt;br&gt;https://doi.org/10.1093/jac/dkr071</mixed-citation></ref><ref id="hanspub.19858-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bressler, A.M., Zimmer, S.M., Gilmore, J.L. and Somani, J. (2004) Peripheral Neuropathy Associated with Prolonged Use of Linezolid. The Lancet Infectious Diseases, 4, 528-531. &lt;br&gt;https://doi.org/10.1016/S1473-3099(04)01109-0.</mixed-citation></ref></ref-list></back></article>